New Novell announced that the marketing application for usinumab injection by Jushi Biotech, a holding subsidiary of the company, has been accepted by the State Drug Administration. Usinumab injection is a wholly human IgG1kappa monoclonal antibody, mainly used to treat plaque-like psoriasis in adults and children. Clinical trial results showed that the drug has good efficacy and safety in treating moderate to severe plaque psoriasis, and is highly consistent with the performance of the original drug Starano®. The drug is expected to be administered every 12 weeks, which has significant clinical application advantages. Currently, the application is based on a critical phase III clinical trial and has been accepted. The marketing of the drug still requires further approval from the State Drug Administration.

New Novell announced that the marketing application for usinumab injection by Jushi Biotech, a holding subsidiary of the company, has been accepted by the State Drug Administration. Usinumab injection is a wholly human IgG1kappa monoclonal antibody, mainly used to treat plaque-like psoriasis in adults and children. Clinical trial results showed that the drug has good efficacy and safety in treating moderate to severe plaque psoriasis, and is highly consistent with the performance of the original drug Starano®. The drug is expected to be administered every 12 weeks, which has significant clinical application advantages. Currently, the application is based on a critical phase III clinical trial and has been accepted. The marketing of the drug still requires further approval from the State Drug Administration.